



an Open Access Journal by MDPI

Advances in Cellular and Molecular Treatment of Autoimmune Diseases

Guest Editors:

Dr. Panagiotis Athanassiou

Department of Rheumatology, St. Paul's Hospital, Thessaloniki, Greece

Prof. Dr. Dimitrios P. Bogdanos

Department of Internal Medicine and Autoimmune Rheumatic Diseases, School of Medicine, University of Thessaly, Larissa, Greece

Dr. Ifigenia Kostoglou-Athanassiou

Asclepeion Hospital, Athens, Greece

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editors

Lately, there is a world-wide increase in the prevalence and incidence of autoimmune diseases. Treatment of autoimmune diseases has been the subject of fruitful research in recent years. Corticosteroids may be applied as early treatment. Disease modifying non-biologic drugs such as methotrexate. leflunomide. sulfasalazine and hydroxychloroguine have been used and may alter disease prognosis. Biologic agents targeting cellular and molecular targets have been introduced in the treatment of autoimmune diseases and have induced disease remission. and may have altered disease progression and long-term disease prognosis. Biologic agents may be used either intravenously or subcutaneously. However, biologic agents are related with a high cost. Therefore, biosimilars of these agents have been introduced in the treatment of autoimmune diseases. The concurrent application of nonbiologic disease modifying agents and biologics is discussed. Currently, there is availability of diverse effective agents targeting cellular and molecular targets in the treatment of autoimmune diseases and has enabled the modification of treatment regimens to the needs of each individual patient.









an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Alexander E. Kalyuzhny

Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (*General Biochemistry, Genetics* and *Molecular Biology*)

Contact Us

Cells Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/cells cells@mdpi.com X@Cells_MDPI